Cue Biopharma (CUE) Receives a Buy from Berenberg Bank

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Cue Biopharma (CUEResearch Report) yesterday and set a price target of $30.00. The company’s shares closed last Thursday at $11.14.

According to TipRanks.com, Shu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.8% and a 26.6% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cue Biopharma with a $29.50 average price target, representing a 167.9% upside. In a report issued on January 3, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $18.42 and a one-year low of $9.65. Currently, Cue Biopharma has an average volume of 316.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Read More on CUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed